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Abstract: Peptidyl mono-fluoromethyl ketones (FMKs) are a class of biologically active molecules
that show potential as both protease inhibitors for the treatment of a range of diseases and as
chemical probes for the interrogation of cellular processes. This review describes the current solid- and
solution-phase routes employed for the synthesis of peptidyl mono-FMKs. In addition, it provides
a brief overview of some of the key applications of FMKs in the fields of chemical biology and
medicinal chemistry.
Keywords: peptide; fluoromethyl ketone; peptide synthesis; peptide modification; fluorine;
therapeutic; probe
1. Introduction
Peptidyl mono-fluoromethyl ketones (FMKs) are a class of biologically active compounds that
have been developed as protease inhibitors [1–5] and as chemical probes for the interrogation of cellular
processes [6–8]. Peptidyl FMKs were first reported in 1985 [9] and have since gained preference in
the field over the corresponding peptidyl chloromethyl ketones (CMKs), largely due to their lower
reactivity towards nucleophiles. For example, peptidyl CMKs have been developed as both cysteine
and serine protease inhibitors (e.g., Figure 1, (1)), but their highly reactive nature often causes issues
with regards to selectivity. As such, for many peptidyl CMKs, indiscriminate binding of nonproteolytic
enzymes leads to undesirable side-effects, rendering them unsuitable for in vivo applications [10].
Peptidyl FMKs are much less prone to nonspecific alkylations due to the intrinsic strength of the C-F
bond making them significantly more selective [9] (Figure 1, (2), (3)). Since their discovery, the number
of synthetic routes that are available to access peptidyl mono-FMKs remains rather limited, particularly
when compared to those that can be used to access the corresponding peptidyl CMKs [11–13] and even
peptidyl tri-fluoromethyl ketone systems (Figure 1, (4)) [14–16].
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reaction. However, this approach did not produce the desired FMK (7), but rather, resulted in a 
nonfluorinated compound (6) along with various unwanted side-products (Scheme 1) [9]. 
 
Scheme 1. Attempted formation of a peptidyl mono-fluoromethyl ketone (FMK) (7) through a 
halogen-exchange reaction [9]. 
Since then, a successful halogen-exchange method has been developed and was reported by 
Kolb et al. in 1986 (Scheme 2) [18]. Initial isolation of 3-phthalimido-1-bromo-4-phenyl-2-butanone 
(8) from N-phthaloyl phenylalanine was achieved through generation of the corresponding 
diazoketone via the acid chloride (not shown). Subsequent bromination of the diazoketone according 
to previously known conditions [19,20] led to the formation of 8. Further reaction of 8 with KF/l8-
crown-6 led to FMK 9 in a 45% yield (Scheme 2). Reduction by sodium borohydride enabled removal 
of the phthaloyl protecting group, however, this simultaneously reduced the ketone functionality 
i re 1. e rese tati e exa les f a e ti l c l r et l et e (1) [12], e ti l fl r et l
ketones (2 [3] an 3 [2]), an a e ti yl tri-fl oro ethyl ketone (4) [15].
This review provides an overview of the current state-of-the-art with regards to solid- and
solution-phase synthetic routes that can be employed for the synthesis of peptidyl mono-FMKs.
In addition, a brief summary of the key applications of this class of compound within the fields of
chemical biology and medicinal chemistry is given. For a more detailed overview of FMKs within the
field of medicinal chemistry, an excellent recent review of this area was published by A. Citarella and
N. Micale [17].
2. Current Synthetic Routes to Peptidyl Mono-FMKs
2.1. Solution-Phase Routes
2.1.1. Halogen-Exchange
An early attempted solution-phase peptidyl mono-FMK synthesis looked to use the displacement
of bromide or chloride with a source of inorganic fluoride in a halogen-exchange reaction. However,
this approach did not produce the desired FMK (7), but rather, resulted in a nonfluorinated compound
(6) along with various unwanted side-products (Scheme 1) [9].
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c e e 1. Attempted formation of a eptidyl ono-fluoro ethyl ketone ( ) (7) t r a
halogen-exchange reaction [9].
Since then, a successful halogen-exchange method has been developed and was reported by Kolb
et al. in 1986 (Scheme 2) [18]. Initial isolation of 3-pht alimido-1-bromo-4-ph nyl-2-butanone (8) from
N-phthaloyl phenylalanin was achieved through generation of the corresponding diazoketone via
the acid chloride (n t show ). Subsequent bromination of the diazoketone according to previously
known c ditions [19,20] led to the formation of 8. F rther reaction of 8 with KF/l8-crown-6 le to
FMK 9 in a 45% yield (Scheme 2). Reduction by sodium borohydride enabled removal of the p thaloyl
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protecting group, however, this simultaneously reduced the ketone functionality which had to be
reinstalled by Swern oxidation (10) [21,22]. Vederas et al. utilised a similar approach for the synthesis
of a 13C-labelled peptidyl FMK probe which was used to investigate the mode of action of the HAV 3C
enzyme [23].
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2.1.2. Synthesis via Direct Fluorination of a iazo Inter ediate
Another initially cce sful attempt in olved the reaction of HF with a diazomethyl
ketone; a method anal gous to that used for the synthesis of CMKs (chloromethyl ketones)
and BMKs (bromom thyl ketones). This reaction, which was attempted on Cbz-Phe-CHN2,
di not yield the desired FMK, but i stead resulted in the formation f the cyclic product
1-oxa-3-aza-4-b nzylcyclohexan-2,5-dione [9,24]. It was found that the use of HF/pyridine [25] allowed
the successful isolation of the desired product. Furthermore, the use of phthaloyl instead of Cbz as a
protecting group also ensured that no a ide proton was present, thus preventing unwanted internal
cyclisation. Generation of the diazo compound (12) was first achieved through the reaction of 11 with
diazomethane in the presence of triethylamine and isobutylchloroformate (Scheme 3). Subsequent
exposure to HF/pyridine led to the isolation of FMK 13. Removal of the phthaloyl group under
reducing conditions allowed peptide chain extension [24], however, the FMK carbonyl functionality
needed to be regenerated in the final step through oxidation.
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2.1.3. Dakin–West Modification
A com only used approach for the synthesis of keto-amides, the Dakin–West reaction [26],
was modified [9] in order t all w for the synthesis of a selection of peptidyl-FMKs, as shown in
Scheme 4 for Bz-DL-Ala-CH2F (19). The isolation of 19 in yields ranging from 20–25% was achieved
through reaction of 18 with fluoroacet c anhydrid i the p esence of triethylamine nd catalytic
Molecules 2020, 25, 5601 4 of 16
amounts of 4-dimethylaminopyridine. However, it was noted that racemisation was unavoidable, and
the method failed to produce the desired product for the valine analogue.
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FMK 36. This pathway to 36 proceeded with an overall yield of 70–75%. A modified version of this 
Sche e 4. For ation of peptidyl ono-F building block Bz- L- la-C 2F (19) via a odified
Dakin– est reaction [9].
2.1.4. Epoxide Ring Opening Approach with Fluoride Source
The synthesis of peptidyl FMKs was also reported by Funeriu and coworkers in 2012. This was
achieved through epoxide ring opening of epichlorohydrin 20 with a fluoride source (KHF2) to
give 21, which was then converted to N-phthalimid-fluoro-alcohol 22 in the presence of potassium
phthalimide [6] (Scheme 5). Subsequent reaction with hydrazine allowed the generation of the free
amine (23), which could then be Fmoc protected to give 24, before oxidation with DMP-afforded FMK
25. Temporary protection of the ketone functionality as a 1,3-dithiane followed by Fmoc deprotection
was employed in order to allow peptide growth to occur. Regeneration of the ketone group was
achieved using bis(trifluoroacetoxy)iodobenzene, giving peptidyl FMK 29 in a quantitative yield.
A modified version of this procedure was utilised by Ellis et al. in 2016 in order to access peptidyl
FMKs to be studied as irreversible protease inhibitors [8].
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2.1.5. Synthetic Pathway Involving Utilisation of a Fluorinated Hemiacetal/Aldehyde
The application of fluorinated hemiacetals/aldehydes has also been explore for accessing peptidyl
FMKs. One particular example of this involves the formation of β-nitroalcohol species 32 derived
from nitro alkane 30 reacting with a fluor nated hemi cetal (31), catalysed by potassium c rbonate
(Scheme 6) [14]. Further reduction with Raney nickel at 50 psi of hydrogen pressur followed by
treatment with conc rated HCl allowed generation of 33 as a mixture of DL, threo, and erythro
diastere mers. After liberation of the hydrochloride salt, p ptide coupling with DCC as the activator
afforded 35. The final step in the process involved a Sarett oxidation, allowing isolation of FMK 36.
This pathway to 36 proceeded with an overall yield of 70–75%. A modified version of this method was
Molecules 2020, 25, 5601 5 of 16
employed by Revesz et al. in 1994 [27]. Chatterjee and coworkers described the preparation of peptidyl
FMKs using a similar procedure [2], and also introduced a new approach which will be detailed in the
next Section 2.1.6 [2].
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dimethylhydroxylamine hydrochloride, triethylamine and BOP. Further reaction with MeMgBr led 
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The synthetic route presented by Cai et l. 06 (Scheme 7) closely resembles the meth dology
already discussed (Scheme 6), with the ke iff r c i t e use of a fluorinated aldehyde instead
of the hemiacetal (31) [4]. Starting fro ester 37, conversion to amide 38 was achieved through the
addition of dimethylamine. Further reaction with 2-fluoroacetaldehyde, which was accessed through
Swern oxidation of the corresponding alcohol, enabled isolation of nitro-alcohol 39. A subsequent
hydrogenation step afforded 40 which could then be coupled to Cbz-Val-OH and finally oxidised to
FMK 42. Similar methodology was later employed by M. L. Forrest et al. in 2012 for accessing an FMK
with a fluorescent moiety attached for cellular imaging purposes [7].
Molecules 2020, 25, x FOR PEER REVIEW 5 of 16 
 
method was employed by Revesz et al. in 1994 [27]. Chatterjee and coworkers described the 
preparation of peptidyl FMKs using a similar procedure [2], and also introduced a new approach 
which will be detailed in the next Section 2.1.6 [2]. 
 
Scheme 6. Isolation of peptidyl FMK 36 via a fluorinated hemiacetal [14]. 
The synthetic route presented by Cai et al. in 2006 (Scheme 7) closely resembles the methodology 
already discussed (Scheme 6), with the key difference being the use of a fluorinated aldehyde instead 
of the hemiacetal (31) [4]. Starting from ester 37, conversion to amide 38 was achieved through the 
addition of dimethylamine. Further reaction with 2-fluoroacetaldehyde, which was accessed through 
Swern oxidation of the corresponding alcohol, enabled isolation of nitro-alcohol 39. A subsequent 
hydrogenation step afforded 40 which could then be coupled to Cbz-Val-OH and finally oxidised to 
FMK 42. Similar methodology was later employed by . L. Forrest et al. in 2012 for accessing an FMK 
with a fluorescent moiety attached for cellular imaging purposes [7]. 
Scheme 7. Synthetic route to peptidyl FMK 42 utilising a fluorinated aldehyde species [4]. 
2.1.6. Synthetic Methodology Employing Silyl Enol Ether Fluorination 
Chatterjee and coworkers described a novel approach for accessing peptidyl FMKs in 1997 
(Scheme 8) [2]. Starting from Cbz-Val-Phe-OH (43), conversion to the Weinreb amide (44) was 
achieved with unavoidable epimerisation at the P1 position in the presence of N,O-
dimethylhydroxylamine hydrochloride, triethylamine and BOP. Further reaction with MeMgBr led 
Scheme 7. Synthetic route to peptidyl FMK 42 utilising a fluorinated aldehyde species [4].
2.1.6. Synthetic Methodology Employing Silyl ol t er l orination
Chatterjee and coworkers described a novel approach for accessing peptidyl FMKs in 1997
(Scheme 8) [2]. Starti g from Cbz-Val-Phe-OH (43), conversion t the Wei reb amid (44) was achieved
with unavoidable epimerisation at the P1 position in the presence of N,O-d methylhydroxylamine
hydrochloride, triethylamine and BOP. Further reaction with MeMgBr led to the successful isolation
Molecules 2020, 25, 5601 6 of 16
of methyl ketone 45. This could then be transformed into the corresponding silyl enol ether and
subsequently fluorinated with F-TEDA-BF4, affording dipeptide FMK 46.
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2.1.7. Synthetic Pathway Involving 1-amino-3-fluoro-propan-2-ol hydrochloride (48)
A literature procedure for accessing peptidyl FMKs, which was reported by Tang et
al. in 2016 (Scheme 9) [5], involves the coupling of a Boc-protected amino acid (47) with
1-amino-3-fluoro-propan-2-ol hydrochloride (48), which was synthesised according to a two-step
procedure (not shown). Amide bond formation between 47 and 48 proceeds through exposure to HATU
under basic conditions (DIPEA). Subsequent Boc deprotection of 49 is achieved by treatment with HCl
in ethyl acetate, allowing for the coupling of the following amino acid. The final step in the process
involves the oxidation of alcohol 51 to FMK 52 in the presence of Dess–Martin periodinane (DMP).
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i fluoromalonate 56 [28]. This method was l ter employed by Vederas et al. in 1997, as shown
in Scheme 10 [23]. After initial generation of mag esiu benzyl fluoromalonate 56 from dimethyl
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fluoromalonate 53 (Scheme 10), further reaction with Boc-N,N-dimethylglutamine (57) in the presence
of 1,1’-carbonyldiimidazole (CDI) afforded 58 without racemisation at the P1 position (Scheme 10).
Subsequent catalytic hydrogenation gave the desired FMK 59.
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et al. [30]. Initial side-chain esterification and subsequent debenzylation of 63 allowed isolation of 
acid 64. Further reaction with CDI followed by addition of enolate 65 and subsequent hydrogenation 
gave FMK 66 in a yield of 68%. This was then Boc-deprotected under acidic conditions and coupled 
to fragment 67 in order to generate the FMK (68). In this case, the Boc group in 68 was removed and 
reacted with BODIPY TMR-OSu, which allowed for the preparation of a fluorescent probe for 
studying yeast peptide N-glycanase activity. 
Scheme 10. Synthesis of F i si benzyl fluoromalonate (56) [23].
Implementation this method logy was late carried out by Scott and coworke s in their
work to explore the use of peptidyl FMKs as covale t nhibitors of MALT1 [3]. Magnesium benzyl
fluor malonate (56) was coupled to a c- r i i it r tected with a 2,2,5,7,8-pentamethylchroman
(Pmc) sulfonyl gro o t e side chain (60) in the presence of CDI (Scheme 11). A one-pot benzyl
ester deprotection and subsequent decarboxylation to the FMK was then achieved through the use of
H2 and Pd/C in ethanol. A final selective Boc deprotection step gave the desired protected arginine
building block (62) which could then be coupled to other amino acid units as required. Unfortunately,
partial racemisation of the arginine residue was observed during the formation of 61.
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Scheme 1 . Sy t of peptidyl FMK building block 62 using magnesium benzyl fluoromalonate
(56) [3].
2.1.9. Synthetic Approach Involving Magnesium Monobenzyl Fluoromalonate Enolate 65
Van der Marel et al. [29] described an approach that made use of monobenzyl fluoromalonate
magnesium enolate 65 as opposed to the neutral magnesium salt (56). The procedure for accessing
FMK 68 (Scheme 12) involves an adapted version of the patented methodol gy described by Palmer et
al. [30]. Initial side-chain esterificati n and subsequent debenzylation of 63 allowed isolation of acid
64. Further reaction with CDI followed by additi n of enolat 65 and subseque t hydrogenation gave
FMK 66 in a yield f 68%. This was then Boc-deprotected und r a idic conditions and coupled to
fragment 67 in order to generate the FMK (68). In this case, the Boc group in 68 was remov d and
reacted with BODIPY TMR OSu, which allowed for the preparation of a fluorescent probe for studying
yeast peptide N-glycanase activity.
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2.2. Solid-Phase Route
At present, only one solid-phase peptide synthesis (SPPS) method for accessing peptidyl
mono-FMKs has been reported in the literature [31]. The approach involves initial formation of
the FMK moiety through utilisation of a halogen-exchange reaction in a similar manner to the work of
Kolb et al. [18] described earlier (Scheme 2). This is followed by attachment to the resin and peptide
elongation. The first part of the process, involving construction of the FMK group from the amino acid
building block Fmoc-Asp(OtBu)-OH (69), is shown in Scheme 13. Firstly, the formation of diazoketone
derivative 70 is achieved via a two-step process involving diazomethane. 70 is converted to the
bromomethyl ketone 71 with HBr and then subsequently transformed into the desired FMK (72) using
TBAF as a fluoride source in the presence of p-toluenesulfonic acid (PTSA). Repeating these steps
using Fmoc-Gly-OH to produce the corresponding FMK analogue resulted in purification difficulties.
As a result, the diazoketone was instead converted to the FMK via the hydroxymethyl ketone instead
of the bromomethyl ketone, as this proved more successful for this particular substrate (not shown
in scheme).
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Scheme 13. Generation of il fr F oc-Asp(OtBu)-OH (69) [31].
In the case of the FMK (72) obtai e fr c- s ( tBu)-OH, because of the acid side-chain,
attachment o the resin could oc ur in a st i anner, allowing for subsequent growth of
the peptide chain and standard acidol ti t e resin. For use in solid-phase synthesis,
tempora y protection of the FMK ketone functionality was required. Th s, h
with methanol in the pr senc of PTSA to give dimethyl ketal 73 with concomitant removal of the tBu
side-chain protecti n.
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As not all amino acids possess a carboxylic acid functional group in their side chain, an alternative
approach needed to be employed for amino acids such as Gly. This modified approach involved the
synthesis of a linker which could be anchored to both the ketone of the FMK using a 1,3-diol and to
the resin via a carboxy group. The linker was made in such a way that it was stable during SPPS,
yet capable of being cleaved under acidic conditions. Figure 2 shows the FMK moiety bound to the
linker (74).
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3. Applications and Uses of Peptidyl Mono-FMKs in Medicinal Chemistry 
3.1. Drug Discovery 
FMKs have shown potential for use in the development of drug therapeutics as well as chemical 
probes for interrogating cellular processes and the identification of protein targets [17,31]. In particular, 
FMKs have proven to be effective covalent protease inhibitors for the treatment of a wide range of 
diseases. These include rheumatoid arthritis, where FMKs with the ability to reduce the severity of 
inflammation and inhibit the extent of bone and cartilage damage have been reported [1,32,33]. Peptidyl 
FMKs have also shown significant promise as therapeutic agents for combating neurodegenerative 
disorders such as Alzheimer’s disease, along with various other illnesses including cancer [5]. 
Proteolytic cleavage of peptides within living organisms by protease enzymes is a vital process for 
maintaining optimum bodily function, with protease enzymes playing a significant role in many 
physiological processes including blood coagulation, digestion, and healing of wounds [34,35]. Despite 
this, if cleavage occurs in a disorderly and uncontrollable manner, the onset of ill health can be observed 
[36]. For this reason, the ability of certain inhibiting molecules to bind selectively to the proteases, 
preventing them from performing these disruptive cleavages, can prove hugely beneficial in the 
treatment of the patient. In addition to this, protease inhibitors can also be used for combating viral 
particles [37], as these too rely on proteolysis to be able to function properly. Peptidyl FMKs are capable 
of binding to these viral protease enzymes [38], blocking their activity and therefore preventing the 
maturation of infectious viral particles. This hinders replication, thus helping to combat disease. 
3.1.1. Peptidyl FMKs for the Treatment of Rheumatoid Arthritis 
The use of peptidyl FMKs for the treatment of rheumatoid arthritis has been studied and 
subsequently reported in the literature [1]. FMKs have been designed that are able to inhibit cathepsin 
B, a cysteine protease, thus helping to reduce the extent of inflammation and combat cartilage and 
bone damage. The extracellular matrix of cartilage consists of proteoglycan and collagen molecules 
assembled in such a way that a rigid gel is formed, enabling joints to function properly. The 
development of arthritis has been associated with the release of cathepsins into inflamed tissues, 
causing destruction of the matrices because of proteoglycan and collagen degradation. This can have 
detrimental effects on the organism, leading to a loss of optimal joint function. 
A selection of peptidyl FMK inhibitors, each consisting of a Phe-Ala moiety with variable N-
terminal blocking groups, was synthesised and found to be effective irreversible inhibitors in vitro. 
The treatment of rats with a single oral dose of 25 mg/kg resulted in a 22–91% reduction in liver and 
kidney cathepsin B levels over a period of just 4 h (Table 1). The change in inhibition observed as a 
result of varying the N-terminal blocking group suggests that it has a significant effect on the 
interaction of the inhibitors with cathepsin B. 
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3. Applications and Uses of Peptidyl Mono-FMKs in Medicinal Chemistry
3.1. Drug Discovery
FMKs have shown potential for use in the development of drug therapeutics as well as chemical
probes for interrogating cellular processes and the identification of protein targets [17,31]. In particular,
FMKs have proven to be effective covalent protease inhibitors for the treatment of a wide range of
diseases. These include rheumatoid arthritis, where FMKs with the ability to reduce the severity of
inflammation and inhibit the extent of bone and cartilage damage have been reported [1,32,33]. Peptidyl
FMKs have also shown significant promise as therapeutic agents for combating neurodegenerative
disorders such as Alzheimer’s disease, along with various other illnesses including cancer [5].
Proteolytic cleavage of peptides within living organisms by protease enzymes is a vital process for
maintaining optimum bodily function, with protease enzymes playing a significant role in many
physiological processes including blood coagulation, digestion, and healing of wounds [34,35]. Despite
this, if cleavage occurs in a disorderly and uncontrollable manner, the onset of ill health can be
observed [36]. For this reason, the ability of certain inhibiting molecules to bind selectively to the
proteases, preventing them from performing these disruptive cleavages, can prove hugely beneficial in
the treatment of the patient. In addition to this, protease inhibitors can also be used for combating
viral particles [37], as these too rely on proteolysis to be able to function properly. Peptidyl FMKs are
capable of binding to these viral protease enzymes [38], blocking their activity and therefore preventing
the maturation of infectious viral particles. This hinders replication, thus helping to combat disease.
3.1.1. Peptidyl FMKs for the Treatment of Rheumatoid Arthritis
The use of peptidyl FMKs for the treatment of rheumatoid arthritis has been studied and
subsequently reported in the literature [1]. FMKs have been designed that are able to inhibit cathepsin
B, a cysteine protease, thus helping to reduce the extent of inflammation and combat cartilage and
bone damage. The extracellular matrix of cartilage consists of proteoglycan and collagen molecules
assembled in such a way that a rigid gel is formed, enabling joints to function properly. The development
of arthritis has been associated with the release of cathepsins into inflamed tissues, causing destruction
of the matrices because of proteoglycan and collagen degradation. This can have detrimental effects on
the organism, leading to a loss of optimal joint function.
A selection of peptidyl FMK inhibitors, each consisting of a Phe-Ala moiety with variable
N-terminal blocking groups, was synthesised and found to be effective irreversible inhibitors in vitro.
The treatment of rats with a single oral dose of 25 mg/kg resulted in a 22–91% reduction in liver
and kidney cathepsin B levels over a period of just 4 h (Table 1). The change in inhibition observed
as a result of varying the N-terminal blocking group suggests that it has a significant effect on the
interaction of the inhibitors with cathepsin B.
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Table 1. % Inhibition of cathepsin B in liver and kidney tissue homogenates treated with 25 mg/kg of a
selection of peptidyl FMKs [1].
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3.1.2. Peptidyl FMKs for the Treatment of Neurological Disorders 
The onset and progression of certain neurological diseases such as Alzheimer’s, stroke, and 
epilepsy has been associated with the presence of activated calpain I in the body [2]. During a stroke, 
the intracellular Ca2+ concentration increases as a result of various biochemical events. This 
subsequently leads to the activation of calpain I which is responsible for degradation of neuronal 
structural proteins. For this reason, the development of calpain I inhibitors is desirable in order to 
prevent neurodegeneration, thus combatting neurological disorders. A selection of peptidyl FMK 
dipeptides with varying amine protecting groups were synthesised and found to be potent 
irreversible inhibitors of calpain I. Interestingly, changing the N-capping group could be used to 
enhance the selectivity of the compound in favour of inhibiting calpain I over cathepsin B and L, 
along with altering potency. The absence of a protecting group was found to give poor inhibition, 
whilst t-Boc appeared to give the best selectivity for calpain I over cathepsin B. Additionally, a 
hydrophobic group was preferred at the P1 position in order for potent inhibition to occur. The 
importance of Leu or Val at P2 was also notable from the results reported. The most potent compound 
tested (k = 276,000 M−1 s−1) (76) along with the FMKs showing the greatest calpain I selectivity (77 and 
78) can be seen in Figure 3. In addition to exhibiting good activity in an assay, these compounds were 
found to be cell permeable and capable of inhibiting intracellular recombinant human calpain I. 
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3.1.2. Peptidyl F the Treatment of Neurological i ders
The on et and progression of ce tai neurological diseases such as Alzheimer’s stroke,
and epilepsy has been ssociated with the presence of activated calpain I in the body [2]. During a
stroke, the intracellular Ca2+ concentration increases as a result of various biochemical events.
This subsequently leads t activation of calpai I which is responsible for degradation of neuronal
structural proteins. For this reason, the development of calpain I inhibi ors is d sirable in order to
prevent neurodegener tion, thus combatti neurological disorders. A selection of p ptidyl FMK
dipeptides with varying amine rotecti g groups were sy thesised d found t be potent irreversible
inhibitors of calpain I. Inter stingly, cha g g the N-capping roup could be u d to enhance the
selectivity of the com u d in favour of inhibiting calpain I over cathepsin B and L, along with altering
potenc . The a sence of a ot cting group was f und t give poor inhibitio , wh lst -B appeared to
give the best selectivity for calpain I over cathepsin B. Additionally, a hydrophobic group was preferred
at the P1 position in order for potent inhibition to occur. T e importance of Leu or Val at P2 was also
notable from th results reporte . The m st potent compound tested (k = 276,000 M−1 s−1) (76) along
with the FMKs showing the greatest c lpai I select vity (77 and 78) a e seen i Figure 3. In addition
to exhibiting good activity in an assay, these compounds were found to be cell permeable and capable
of inhibiting intracellular recombinant human calpain I.
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3.1.3. Peptidyl FMKs as Inhibitors of MALT1 Paracaspase
The paracaspase enzyme MALT1 plays a key role in immune response through the activation
of lymphocytes and other immune cells [3]. Despite the importance of these processes for healthy
bodily function, if they occur in an abnormal manner, this can lead to the development of lymphoid
malignancies. For this reason, the synthesis of inhibitors that target MALT1 proteases has proved an
attractive method for the treatment of these tumours. Peptidyl-FMKs such as 79 (Figure 4) have shown
potential for this purpose. The P1 Arg residue was found to be essential due to its interaction with
the acidic residues in the target protein, whilst Leu at P4 helped by occupying a hydrophobic pocket.
Although potent inhibitors have now been successfully developed for targeting MALT1 enzymes
in vivo, the acquisition of orally available inhibitors remains an ongoing challenge.
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3.1.4. Dipeptidyl Glutaminyl FMKs as SARS-CoV Inhibitors
In 2003, an outbreak of SARS (Severe Acute Respiratory Syndrome) occurred as a result of
the spread of coronavirus pathogen SARS-CoV. The virus, which leads to respiratory difficulties,
was responsible for causing nearly 800 deaths; a value close to 10% of all confirmed cases in 2003.
In 2006, S. X. Cai et al. synthesised a selection of dipeptidyl glutaminyl FMKs to be investigated
as potential SARS-CoV inhibitors [4]. The viral cysteine protease enzyme Mpro [39] is essential for
viral replication, an wa thus identified as a possible drug target. Antiviral activity was evaluated
through cytopathogenic effect (CPE) inhibition in SARS-CoV infected Vero a d CaCo2 cultu s.
Cbz-Leu-Gln(NMe2)-FMK (80a) was found to be the most potent inhibitor, with an EC50 value of
2.5 µM in Vero cells (infected with strain 6109), low cellular toxicity, and a selectivity index of >40
(Table 2). FMKs 80b and 80c also showed some promising EC50 values (Table 2), and 80c was also
found to exhibit low toxicity in mice, suggesting that inhibitors should possess good safety profiles for
further efficacy studies to be performed in animals.
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Table 2. EC50, CC50, and Selectivity Index (SI) values for a selection of dipeptidyl glutaminyl FMKs in
SARS-CoV-infected Vero and CaCo2 cultures [4].
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3.2. Probes for Cellular Interrogation
In addition to their applications in the field of rug discovery, peptidyl FMKs have also been
widely employed as hemical tools for the in errogati n of biological systems [31]; for example,
the elucidation of th structure and binding requi ements fo pro ea e receptors in order to design
d ugs with greater selectivity and potency. Useful information c n also be gained in r l tion to the
active site selectivity of individual proteases within broader protease lass s. This can be ac ieved
through obse ving the ature of the bi ding i teractions when amino acid groups n the p ptide
region of t e peptidyl-FMK chain are varied until the binding requirements are fully satisfied [24].
Conjugation of dyes into th FMK structure, an example of which is shown in Figure 5 (81), has also
been explored in ord r to allow for fluorescent imaging of cellular activity such as apoptosis [7].
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Ellis and coworkers describe another example in which peptidyl FMKs are useful for understanding
the structural binding requirements and properties of a target enzyme [8]. In this case, inhibitor 82
(Figure 6) was synthesised and found to be a potent and selective irreversible inhibitor of PKACα,
a kinase enzyme. The structure of the inhibitor consists of an electrophilic fluoromethyl ketone moiety
attached to a substrate-competitive inhibitor scaffold. This means that if the FMK binds in a region in
which a reactive cysteine residue is present, the nucleophilic cysteine will attack the electrophilic FMK,
causing inhibition. The nature of the peptide scaffold also plays a key role as it allows the peptide to
bind in the vicinity of the reactive cysteine, an essential requirement for successful inhibition. As a
result, inhibitor 82 is capable of covalently binding to and modifying a cysteine residue at the binding
site of the enzyme. The incorporation of rhodamine B, a fluorescent tag, was employed in order to
allow the inhibitor-substrate adduct to be observed, thus helping to confirm that the mechanism of
inhibition occurs in an irreversible manner. In this way, the peptidyl FMK developed was found to be
a useful tool for studying PKACα activity.
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4. Conclusions
As highlighted, peptidyl mono-FMKs have been reported to exhibit promising therapeutic activity
against a range of diseases including Rheumatoid arthritis, neurological diseases such as Alzheimer’s,
lymphoid malignancies, and the SARS-CoV viral pathogen. Furthermore, FMKs can also be used
as chemical probes for studying a range of cellular processes. The multifunctional nature of these
biologically relevant FMK warheads, coupled with the fact that they are significantly more selective than
the analogous chloromethyl-ketone-based inhibitors, makes them attractive moieties with potential
utility in a wide range of applications including in vivo.
Given their applications in these aforementioned areas, a range of synthetic approaches have
been developed to access FMKs. The key synthetic solid- and solution-phase routes discussed in this
review for accessing peptidyl mono-fluoromethyl ketones (FMKs) are summarised in Figure 7.
These include halogen exchange methods (Figure 7a [22,23], diazomethyl ketone fluorination
(Figure 7b) [24], a modified Dakin–West reaction (Figure 7c) [9], epoxide ring opening with a
fluoride source (Figure 7d) [6,8], fluorination of silyl enol ethers (Figure 7e) [2], utilisation of a
fluorinated hemiacetal/aldehyde (Figure 7f) [4,7,14,27], and the use of magnesium fluoromalonates
(Figure 7g) [3,23,28–30]. Additionally, the use of a linker has been employed where appropriate for
the synthesis of peptidyl FMKs by solid-phase peptide synthesis (Figure 7h) [31]. With many of these
approaches suffering from low overall yields, racemisation, and incompatibility with solid phase
peptide synthesis (SPPS) methodology, there is clearly still scope for the future development of new
synthetic routes in this area.
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